Search results
Results from the WOW.Com Content Network
Agent Orange Study of 1979 On December 6, 1979, the 96th United States Congress passed H.R. 3892, better known as Veterans Health Programs Extension and Improvement Act of 1979 . [ 6 ] The Title 38 amendment, better known as Title III: Veterans' Administration Medical Personnel Amendments and Miscellaneous Provisions , was enacted into law by ...
Through this process, the list of 'presumptive' conditions has grown since 1991, and currently the U.S. Department of Veterans Affairs has listed prostate cancer, respiratory cancers, multiple myeloma, type II diabetes mellitus, Hodgkin's disease, non-Hodgkin's lymphoma, soft tissue sarcoma, chloracne, porphyria cutanea tarda, peripheral ...
For premium support please call: 800-290-4726 more ways to reach us
The Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act of 2022, known as the Honoring our PACT Act of 2022, or even more colloquially as "the PACT Act," is an Act of Congress that authorized $797 billion [1] in spending to significantly expand (the scope of benefits eligibility, for existing beneficiaries) and extend (benefits to newly eligible ...
This list focuses on the hazard linked to the agents. This means that while carcinogens are capable of causing cancer, it does not take their risk into account, which is the probability of causing a cancer, given the level of exposure to this carcinogen. [2] The list is up to date as of January 2024. [3]
[22] More recently, the USDVA lists several forms of cancer as presumptive conditions for burn pit exposures. [4] One study using Burn Pits 360's registry found that there is a higher rate of proportionate cancer mortality among deceased veterans. [23]
The WHO's Essential Medicines List, which includes treatments that the WHO regards as global standards that should be available everywhere, aims to help governments make the best choices for their ...
Non-small cell lung cancer and pancreatic cancer. Skin reactions, diarrhoea, GI bleeds, anaemia, dehydration, interstitial lung disease (uncommon), hepatic failure (rare), hepatorenal syndrome (rare), GI perforation (rare) and ulcerative keratitis (rare). Gefitinib: PO: EGFR inhibitor. EGFR-mutation positive non-small cell lung cancer.